Assessment of antiviral properties of peramivir against H7N9 avian influenza virus in an experimental mouse model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7255-7264

  Farooqui, Amber ^a,b,c   Huang, Linxi ^a   Wu, Suwu ^d   Cai, Yingmu ^a   Su, Min ^a   Lin, Pengzhou ^a   Chen, Weihong ^d   Fang, Xibin ^d   Zhang, Li ^a   Liu, Yisu ^a   Zeng, Tiansheng ^a   Paquette, Stephane G ^b,e   Khan, Adnan ^a,c   Kelvin, Alyson A ^b   Kelvina, David J ^b,c,e  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c SHANTOU UNIVERSITY   (China)

^d SHANTOU CENTRAL HOSPITAL   (China)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PERAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; OSELTAMIVIR; SIALIDASE; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ERADICATION; DRUG EFFICACY; FEMALE; IN VIVO STUDY; INFLUENZA A VIRUS (H7N9); MOUSE; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SINGLE DRUG DOSE; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DOG; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG; MDCK CELL LINE; METABOLISM; MORTALITY; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CYCLOPENTANES; DOGS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INJECTIONS, INTRAMUSCULAR; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED C57BL; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84954531039     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01885-15     Document Type: Article

References (50)

1. Guan Y, Farooqui A, Zhu H, Dong W, Wang J, Kelvin DJ. 2013. H7N9 incident, immune status, the elderly and a warning of an influenza pandemic. J Infect Dev Ctries 7: 302-307. http://dx.doi.org/10.3855/jidc.3675.
2. Chen E, Chen Y, Fu L, Chen Z, Gong Z, Mao H, Wang D, Ni M, Wu P, Yu Z, He T, Li Z, Gao J, Liu S, Shu Y, Cowling BJ, Xia S, Yu H. 2013. Human infection with avian influenza A (H7N9) virus re-emerges in China in winter 2013. Euro Surveill 18: 20616.
3. WHO. 2015. Human infection with avian influenza A(H7N9) virus- China. World Health Organization, Geneva, Switzerland.
4. Gao H-N, Lu H-Z, Cao B, Du B, Shang H, Gan J-H, LuS-H, Yang Y-D, Fang Q, Shen Y-Z. 2013. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 368: 2277-2285. http://dx.doi.org/10.1056/NEJMoa1305584.
5. China Health and Family Planning Commission. 2015. National statutory infectious diseases overview. China Health and Family Planning Commission, Beijing, China.
6. Center for Health Protection. 2015. Avian influenza report, reporting period: February 1, 2015-February 7, 2015 (week 6). Center for Health Protection, Department of Health, Hong Kong Special Administrative Region.
7. Chang S-Y, Lin P-H, Tsai J-C, Hung C-C, Chang S-C. 2013. The first case of H7N9 influenza in Taiwan. Lancet 381: 1621. http://dx.doi.org/10 .1016/S0140-6736(13)60943-5.
8. Public Health Agency of Canada. 2015. Government of Canada and British Columbia confirm case of H7N9 avian influenza in Canada. Public Health Agency of Canada, Government of Canada, Vancouver, Canada.
9. Rosen JB, Rota JS, Hickman CJ, Sowers SB, Mercader S, Rota PA, Bellini WJ, Huang AJ, Doll MK, Zucker JR, Zimmerman CM. 2014. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis 58: 1205-1210. http://dx.doi.org/10 .1093/cid/ciu105.
10. Zhu H, Wang D, Kelvin D, Li L, Zheng Z, Yoon S-W, Wong S-S, Farooqui A, Wang J, Banner D, Chen R, Zheng R, Zhou J, Zhang Y, Hong W, Dong W, Cai Q, Roehrl MH, Huang SS, Kelvin AA, Yao T, Zhou B, Chen X, Leung GM, Poon LL, Webster RG, Webby RJ, Peiris JS, Guan Y, Shu Y. 2013. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 341: 183-186. http://dx.doi.org/10.1126/science.1239844.
11. Qi X, Qian Y-H, Bao C-J, Guo X-L, Cui L-B, Tang F-Y, Ji H, Huang Y, Cai P-Q, Lu B, Xu K, Shi C, Zhu FC, Zhou MH, Wang H. 2013. Probable person to person transmission of novel avian influenza A (H7N9) virus in eastern China, 2013: Epidemiological investigation. BMJ 347: F4752. http://dx.doi.org/10.1136/bmj.f4752.
12. Hay AJ, Hayden FG. 2013. Oseltamivir resistance during treatment of H7N9 infection. Lancet 381: 2230-2232. http://dx.doi.org/10.1016/S0140 -6736(13)61209-X.
13. Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM. 2013. Influenza A (H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 4: 2854. http://dx.doi.org/10.1038/ncomms3854.
14. Leung YH, To MK, Lam TS, Yau SW, Leung OS, Chuang SK. 2015. Epidemiology of human influenza A(H7N9) infection in Hong Kong. J Microbiol Immunol Infect 2015: S1684-1182(15)00772-0. http://dx.doi .org/10.1016/j.jmii.2015.06.004.
15. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, Xiang N, Chen E, Tang F, Wang D. 2014. Epidemiology of human infections with avian influenza A (H7N9) virus in China. N Engl J Med 370: 520-532. http://dx.doi.org/10 .1056/NEJMoa1304617.
16. Liu X, Li T, Zheng Y, Wong KW, Lu S, Lu H. 2013. Poor responses to oseltamivir treatment in a patient with influenza A (H7N9) virus infection. Emerg Microbes Infect 2: E27. http://dx.doi.org/10.1038/emi .2013.30.
17. China Health and Family Planning Commission. 2014. H7N9 influenza in humans; a treatment plan (2014). China Health and Family Planning Commission, Beijing, China.
18. Baranovich T, Burnham AJ, Marathe BM, Armstrong J, Guan Y, Shu Y, Peiris JM, Webby RJ, Webster RG, Govorkova EA. 2014. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis 209: 1343-1353. http://dx.doi.org/10.1093/infdis/jit554.
19. Cao R-Y, Xiao J-H, Cao B, Li S, Kumaki Y, Zhong W. 2014. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antivir Chem Chemother 23: 237-240. http://dx.doi.org/10.3851/IMP2672.
20. Birnkrant D, Cox E. 2009. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 361: 2204-2207. http://dx.doi.org/10.1056/NEJMp0910479.
21. Hernandez JE, Adiga R, Armstrong R, Bazan J, Bonilla H, Bradley J, Dretler R, Ison MG, Mangino JE, Maroushek S. 2011. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. Clin Infect Dis 52: 695-706. http://dx.doi.org/10.1093/cid/cir001.
22. Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, Shimada J. 2011. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 55: 2803-2812. http://dx.doi.org/10.1128/AAC.01718-10.
23. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H. 2012. Clinical effectiveness of neuraminidase inhibitors- oseltamivir, zanamivir, laninamivir, and peramivir- for treatment of influenza A (H3N2) and A (H1N1) pdm09 infection: An observational study in the 2010-2011 influenza season in Japan. J Infect Chemother 18: 858-864. http://dx.doi.org/10.1007/s10156-012-0428-1.
24. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen H-L, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Zhang X, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381: 2273-2279. http://dx.doi.org/10.1016/S0140-6736(13)61125-3.
25. Farooqui A, Leon AJ, Huang L, Wu S, Cai Y, Lin P, Chen W, Fang X, Zeng T, Liu Y. 2015. Genetic diversity of the 2013-14 human isolates of influenza H7N9 in China. BMC Infect Dis 15: 109. http://dx.doi.org/10 .1186/s12879-015-0829-8.
26. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368: 1888-1897. http://dx.doi.org/10.1056/NEJMoa1304459.
27. Lipatov AS, Krauss S, Guan Y, Peiris M, Rehg JE, Perez DR, Webster RG. 2003. Neurovirulence in mice of H5N1 influenza virus genotypes isolated from Hong Kong poultry in 2001. J Virol 77: 3816-3823. http://dx .doi.org/10.1128/JVI.77.6.3816-3823.2003.
28. Plourde JR, Pyles JA, Layton RC, Vaughan SE, Tipper JL, Harrod KS. 2012. Neurovirulence of H5N1 infection in ferrets is mediated by multifocal replication in distinct permissive neuronal cell regions. PLoS One 7: E46605. http://dx.doi.org/10.1371/journal.pone.0046605.
29. Belser JA, Gustin KM, Pearce MB, Maines TR, Zeng H, Pappas C, Sun X, Carney PJ, Villanueva JM, Stevens J, Katz JM, Tumpey TM. 2013. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501: 556-559. http://dx.doi.org/10.1038/nature12391.
30. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. 2013. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501: 551-555. http://dx.doi.org/10.1038/nature12392.
31. Mok CKP, Lee HHY, Chan MCW, Sia SF, Lestra M, Nicholls JM, Zhu H, Guan Y, Peiris JMS. 2013. Pathogenicity of the novel A/H7N9 influenza virus in mice. mBio 4: E00362-13. http://dx.doi.org/10.1128/mBio .00362-13.
32. Zhang H, Li X, Guo J, Li L, Chang C, Li Y, Bian C, Xu K, Chen H, Sun B. 2014. The PB2 E627K mutation contributes to the high polymerase activity and enhanced replication of H7N9 influenza virus. J Gen Virol 95: 779-786. http://dx.doi.org/10.1099/vir.0.061721-0.
33. Marjuki H, Mishin VP, Chesnokov AP, Juan A, Fry AM, Villanueva J, Gubareva LV. 2014. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis 210: 435-440. http://dx.doi.org/10 .1093/infdis/jiu105.
34. Whitley R, Laughlin A, Carson S, Mitha E, Tellier G, Stich M, Elder J, Alexander WJ, Dobo S, Collis P, Sheridan WP. 15 October 2014. Single dose peramivir for the treatment of acute seasonal influenza: Integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther http://dx.doi.org/10.3851/IMP2874.
35. Bantia S, Upshaw R, Babu Y. 2011. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme. Antiviral Res 91: 288-291. http://dx.doi.org/10.1016/j.antiviral .2011.06.010.
36. Hayden F. 2009. Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 48: S3-S13. http://dx.doi.org/10 .1086/591851.
37. Abed Y, Pizzorno A, Boivin G. 2012. Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation. Antimicrob Agents Chemother 56: 4375-4380. http://dx.doi.org/10.1128/AAC .00753-12.
38. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. 2006. Antiinfluenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 69: 39-45. http://dx.doi.org/10.1016/j.antiviral .2005.10.002.
39. Feng L, Wu J, Liu X, Yang P, Tsang T, Jiang H, Wu P, Yang J, Fang V, Qin Y, Lau EH, Li M, Zheng J, Peng Z, Xie Y, Wang Q, Li Z, Leung GM, Gao GF, Yu H, Cowling BJ. 2014. Clinical severity of human infections with avian influenza A (H7N9) virus, China, 2013/14. Euro Surveill 19: 20984.
40. Tang X, He H, Sun B, Wan J, Ban C, Zhang C, Wang S, Xia J, Li J, Liu Y, Cao B, Tong Z. 2015. ARDS associated with pneumonia caused by avian influenza A H7N9 virus treated with extracorporeal membrane oxygenation. Clin Respir J 9: 380-384. http://dx.doi.org/10.1111/crj.12140.
41. Yu H, Cowling BJ, Feng L, Lau EH, Liao Q, Tsang TK, Peng Z, Wu P, Liu F, Fang VJ. 2013. Human infection with avian influenza A H7N9 virus: An assessment of clinical severity. Lancet 382: 138-145. http://dx.doi .org/10.1016/S0140-6736(13)61207-6.
42. Uyeki T. 2009. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 361: E110. http://dx.doi.org/10.1056/NEJMopv0910738.
43. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ. 2009. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A 106: 14063-14068. http://dx.doi.org/10 .1073/pnas.0900096106.
44. Li S, Schulman J, Itamura S, Palese P. 1993. Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. J Virol 67: 6667-6673.
45. Drago L, Attia MW, DePiero A, Bean C. 2005. Influenza A-associated meningoencephalitis. Pediatr Emerg Care 21: 437-439. http://dx.doi.org/10.1097/01.pec.0000169434.98819.05.
46. Hayase Y, Tobita K. 1997. Influenza virus and neurological diseases. Psychiatry Clin Neurosci 51: 181-184. http://dx.doi.org/10.1111/j.1440 -1819.1997.tb02580.x.
47. Togashi T, Matsuzono Y, Narita M, Morishima T. 2004. Influenzaassociated acute encephalopathy in Japanese children in 1994-2002. Virus Res 103: 75-78. http://dx.doi.org/10.1016/j.virusres.2004.02.016.
48. Lu S, Xi X, Zheng Y, Cao Y, Liu X, Lu H. 2013. Analysis of the clinical characteristics and treatment of two patients with avian influenza virus (H7N9). Biosci Trends 7: 109-112.
49. Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN, Dziuba N, Holbrook MR, Zhang L, Kilpatrick JM. 2008. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374: 198-209. http://dx.doi.org/10.1016/j.virol.2007.12.029.
50. Barroso L, Treanor J, Gubareva L, Hayden FG. 2005. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: Randomized, controlled trials for prophylaxis and treatment. Antiviral Ther 10: 901-910.